Original ArticleImmune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
Keywords
Cited by (0)
Cite this article as: Kim RY, Mitra N, Bagley SJ, et al. Immune checkpoint inhibitor uptake in real-world patients with malignant pleural mesothelioma. JTO Clin Res Rep. 2021;2:100188.
Disclosure: Dr. Bagley reports receiving research funding to his institution from Eli Lilly and Company, Incyte Corp, GlaxoSmithKline, and Novocure and having a consulting role with Bayer and Novocure outside of the submitted work. Dr. Marmarelis reports receiving research funding to her institution from Eli Lilly and Company, Trizell, and AstraZeneca; having a consulting role with AstraZeneca, Novocure, and Boehringer Ingelheim; having stock in Gilead Sciences, Portola Pharmaceuticals, Merck, Bluebird Bio, Johnson & Johnson, and Pfizer; and receiving previous medical writing support from Novartis outside of the submitted work. Dr. Haas reports having a scientific advisory board role with Bronx Medical outside of the submitted work. Dr. Vachani reports receiving research funding to his institution from Allegro Diagnostics, Integrated Diagnostics, Janssen Research & Development, MagArray, and Bronchus Medical; having a consulting role with Allegro Diagnostics, Johnson & Johnson, Novocure, Ethicon, and AbbVie; and receiving travel support from Intuitive Surgical outside of the submitted work. The remaining authors declare no conflict of interest.